Topic
Topic
Upadacitinib met its primary endpoint in the JAKPPPOT trial for palmoplantar pustulosis, per Medscape. The oral selective JAK1 inhibitor, already approved across rheumatology, gastroenterology and at…
Placebo-adjusted EASI-75 gains of 40.8–51.8 points for upadacitinib vs 13.4 for nemolizumab at Week 16 in an AbbVie-funded MAIC p…
Long-term extension data show repigmentation maintained through 76 weeks in non-segmental vitiligo patients receiving oral upadac…
David Gleeson, BM BCH, PhD, calls upadacitinib a feasible option for palmoplantar pustulosis, extending the JAK1 inhibitor's reac…
Upadacitinib 15 mg daily cleared refractory ARPC in a stage 4 CKD patient after dupilumab triggered paradoxical worsening within…
A Frontiers case report documents long-term upadacitinib therapy in one patient with atopic dermatitis, bullous pemphigoid and al…
Week-76 data from the phase 3 Viti-Up trials show upadacitinib drove continued facial and total-body repigmentation in nonsegment…
A Frontiers case report documents effective treatment of concurrent psoriasis and lichen planus with the JAK1 inhibitor upadaciti…